India wants to aggressively intensify its coronavirus detection capacity because it cannot block or wave new active instances affecting hospitals, according to the head of one of the country’s largest drug manufacturers.
While some states get better results than others, in general, “we are well below the control levels of other countries,” said Kiran Mazumdar-Shaw, founder and president of Biocon Ltd. , Thursday at the Bloomberg India Economic Forum.
Visit our coronavirus here for the latest updates.
“We want to accentuate our trials; the number of active instances is manageable at this point, but if the active instances start to increase, we just don’t have the capacity. “
India, which imposed the world’s largest national lockout in response to the pandemic in March, ignored the growing number of infections when it began to remove restrictions, Mazumdar-Shaw said. Today, 7 million more people in this South Asian country have become inflamed with Covid-19, the world’s largest epidemic of the moment.
With around 830 tests consistent with millions, india’s existing virus detection rates are among the lowest in the world, according to johns Hopkins University’s latest knowledge. economy that through 24% in the quarter ended June.
“We do this ad hoc, reviews matter and science is not rationally tested,” said Mazumdar-Shaw, 67, who in August said she was inflamed with Covid-19 and had suffered mild symptoms. He advised an early diagnosis to treat the infection. and faster.
Fortunately, India has a young population that has reduced the number of deaths, such as a giant capacity for vaccine production, he said.
The country’s goal will be to expand the logistics of the bloodless chain to distribute vaccines throughout India, Mazumdar-Shaw said.
Read more:
Indian cinemas reopen after seven months of closure amid a coronavirus pandemic
Coronavirus: India Reports Lowest Number of COVID-19 Deaths in Weeks